welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: September 2012
estimated completion: August 2016
size / enrollment: 53
The purpose of this tissue bank is to collect blood and skin samples from participants who are diagnosed with Duchenne muscular dystrophy (DMD) and carry one of nine specific changes in the dystrophin gene. The specific dystrophin changes that we are interested in studying are those that would work with exon-skipping therapies in patients with DMD, specifically deletions of the follow exons: 10-52, 13-50, 29-50, 43-52, 44, 43-50, 45-50, 45-52, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-60, 47-50, 47-52, 48-50, 49-50, 50, 52, 52-63, 48-52, 49-52, 50-52.
These blood and skin samples will be held in a tissue bank at Carolinas Medical Center for future DMD research.
- Tissue Collection [ Time Frame: 1 day ]
Collection of blood, skin and optional muscle samples
• Age 4 and above
• Diagnosis of DMD with a confirmed out-of-frame dystrophin gene deletions that could be corrected by skipping exon 45, 51, or 53 based on past genetic testing.
exclusion criteria: Investigator assessment of inability to comply with blood and skin sample collection
Rimeporide in Patients With Duchenne Muscular DystrophyIn Duchenne Muscular Dystrophy (DMD) the...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
First targeted treatment success for Duchenne muscular dystrophyhttps://www.youtube.com/watch?v=tkxTn46_...
Rimeporide: safety, tolerability and pharmacokinetic results from a phase Ib study in DMD boys as well as explorator...In Duchenne muscular dystrophy, impaired...
First Duchenne Drug Approved by the FDAhttps://www.youtube.com/watch?v=xQWfXKL1...
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...